| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$12,259,884 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$12,259,884 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 6 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-04-28 |
4 |
AS |
$120.00 |
$900,000 |
D/D |
(7,500) |
106,011 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-06-05 |
4 |
OE |
$72.14 |
$541,050 |
D/D |
7,500 |
113,511 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-06-05 |
4 |
AS |
$130.00 |
$975,000 |
D/D |
(7,500) |
106,011 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-25 |
4 |
AS |
$229.41 |
$1,748,990 |
D/D |
(7,572) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-18 |
4 |
AS |
$210.11 |
$1,657,590 |
D/D |
(7,825) |
39,033 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-10-01 |
4 |
OE |
$63.14 |
$668,968 |
D/D |
10,595 |
10,595 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-10-01 |
4 |
AS |
$106.56 |
$1,141,531 |
D/D |
(10,595) |
0 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-08-19 |
4 |
OE |
$86.52 |
$1,290,681 |
D/D |
12,501 |
36,212 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-08-19 |
4 |
AS |
$186.37 |
$2,329,976 |
D/D |
(12,501) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$3,206,563 |
D/D |
(13,308) |
57,002 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-06-29 |
4 |
OE |
$86.52 |
$1,171,397 |
D/D |
13,445 |
83,444 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,680 |
45,718 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2016-02-02 |
4 |
A |
$0.01 |
$144 |
D/D |
14,416 |
89,416 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2015-11-18 |
4 |
OE |
$63.14 |
$1,014,600 |
D/D |
15,000 |
90,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2015-11-18 |
4 |
AS |
$130.00 |
$1,950,000 |
D/D |
(15,000) |
75,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-11 |
4 |
AS |
$243.36 |
$4,191,771 |
D/D |
(17,032) |
39,970 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-07-19 |
4 |
OE |
$155.57 |
$3,096,948 |
D/D |
17,765 |
53,942 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-07-19 |
4 |
AS |
$286.72 |
$5,156,730 |
D/D |
(17,865) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-07-16 |
4 |
AS |
$182.00 |
$4,254,250 |
D/D |
(23,375) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-07-16 |
4 |
OE |
$131.89 |
$3,082,929 |
D/D |
23,375 |
62,488 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
26,641 |
76,402 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-07-19 |
4 |
OE |
$81.54 |
$2,448,338 |
D/D |
28,979 |
134,990 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-07-19 |
4 |
AS |
$161.00 |
$4,665,619 |
D/D |
(28,979) |
106,011 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
31,020 |
70,133 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,108 |
65,697 |
0 |
- |
|
157 Records found
|
|
Page 6 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
